President Donald Trump has publicly blamed the Federal Reserve's interest rates hikes for holding back U.S. economic growth.The Fedread more
China's President Xi Jinping arrived in Pyongyang on Thursday morning for a state visit to North Korea — the first by a Chinese state leader in 14 years. Experts say the move...Asia Politicsread more
Gold prices spiked in the afternoon of Asian trading hours on Thursday after a dovish U.S Federal Reserve opened the door to further rate cuts, and the 10-year Treasury yield...Metalsread more
The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Waymo has signed a deal with Renault and Nissan to develop self-driving cars and trucks for use in France, Japan and possibly other countries in Asia, including China, the...Autosread more
"No U.S. drone was operating in Iranian airspace today," a U.S. Central Command spokesman said, according to NBC News.World Politicsread more
The Fed left interest rates unchanged at its monetary policy meeting. The U.S. central bank did, however, drop the word "patient " from its statement and said it would "act as...Asia Marketsread more
As the presidents of U.S. and China near a highly anticipated meeting on trade, the gap in both sides' expectations regarding a deal remains wide.World Politicsread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday.Bondsread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
Bristol-Myers Squibb said on Wednesday its experimental drug helped reduce the severity of the most common form of psoriasis in a mid-stage trial.
The study tested the drug, BMS-986165, in 267 patients with plaque psoriasis, a chronic condition that causes dry, red skin lesions covered with silvery scales.
After 12 weeks, between 67 percent and 75 percent of patients given a 3-milligram dose twice daily, or a higher dose, showed reduction on a scale called PASI-75 that is considered the benchmark of main goals for most psoriasis clinical trials.
The PASI-75 scale showed reduction versus 7 percent in the placebo group. It measures the effectiveness of a drug by recording how many patients achieve a reduction in the area affected and severity of their psoriasis.
The drug is a tyrosine kinase 2 inhibitor, a class of medicines that work to regulate overactive immune responses that drive autoimmune diseases.
Three cases of serious side effects were reported, but none of those were in patients given the 6-mg and the 12-mg doses, the highest being tested, the company said.
Bristol-Myers said it plans to study the drug's use in a "wide spectrum of immune-mediated diseases", saying currently only few oral treatment options are available.
The company is currently enrolling patients for a late-stage trial and also testing BMS-986165 for use in patients with lupus or Crohn's disease. An approval by the U.S. Food and Drug Administration for the plaque psoriasis treatment will offer Bristol-Myers, which relies heavily on its blockbuster cancer drug Opdivo, a chance to diversify its portfolio.
The FDA earlier this year declined to approve Bausch Health's plaque psoriasis lotion Duobrii and analysts now expect that drug to hit market only after 2019.